rs727504681
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_033118.4(MYLK2):c.344A>C(p.Gln115Pro) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000157 in 1,460,574 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_033118.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -6 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome AF: 0.0000157 AC: 23AN: 1460574Hom.: 1 Cov.: 32 AF XY: 0.0000151 AC XY: 11AN XY: 726592
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not specified Uncertain:2
Variant classified as Uncertain Significance - Favor Benign. The p.Gln115Pro var iant in MYLK2 has been identified by our laboratory in 1 individual with bi-atri al and right ventricle dilation and EKG abnormalities who also carried another d isease causing variant in another gene. It was absent from large population stud ies. Glutamine (Gln) at position 115 is not conserved in evolution and Chinese h amster, golden hamster, and cape golden mole have a proline (Pro) at this positi on, raising the possibility that this change may be tolerated. Additional comput ational analyses do not provide strong support for or against an impact to the p rotein. In summary, while the clinical significance of the p.Gln115Pro variant i s uncertain, the presence of the variant amino acid in other mammals suggests th at it is more likely to be benign. -
The c.344A>C (p.Q115P) alteration is located in exon 3 (coding exon 2) of the MYLK2 gene. This alteration results from a A to C substitution at nucleotide position 344, causing the glutamine (Q) at amino acid position 115 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
not provided Uncertain:1
Has not been previously published as pathogenic or benign to our knowledge; Reported in ClinVar as a variant of uncertain significance (ClinVar Variant ID# 179165; Landrum et al., 2016); Not observed in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant does not alter protein structure/function -
Hypertrophic cardiomyopathy 1 Uncertain:1
This sequence change replaces glutamine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 115 of the MYLK2 protein (p.Gln115Pro). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with MYLK2-related conditions. ClinVar contains an entry for this variant (Variation ID: 179165). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt MYLK2 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at